These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1504663)

  • 1. IL-2 gene transduction in malignant cells: applications in cancer containment.
    Roth C; Mir L; Cressent M; Quintin-Colonna F; Ley V; Fradelizi D; Kourilsky P
    Bone Marrow Transplant; 1992; 9 Suppl 1():174-5. PubMed ID: 1504663
    [No Abstract]   [Full Text] [Related]  

  • 2. Interleukin 2 in cancer therapy.
    Testa U; Montesoro E; Bulgarini D; Samoggia P; Masciulli R; Habetswallner D; Carè A; Mariani G; Giannella G; Boccoli G
    Ann Ist Super Sanita; 1990; 26(3-4):283-334. PubMed ID: 2091501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local IL-4 delivery enhances immune reactivity to murine tumors: gene therapy in combination with IL-2.
    Pippin BA; Rosenstein M; Jacob WF; Chiang Y; Lotze MT
    Cancer Gene Ther; 1994 Mar; 1(1):35-42. PubMed ID: 7621236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer.
    Tahara H; Lotze MT
    Gene Ther; 1995 Mar; 2(2):96-106. PubMed ID: 7719935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-2 and cancer--physiological and pharmacological uses.
    Huland E
    Folia Biol (Praha); 2001; 47(4):111-2. PubMed ID: 11508853
    [No Abstract]   [Full Text] [Related]  

  • 6. [Experimental study on the optimal treatment schedule for combination of BRM (immunostimulators, cultured killer cells or interleukin-2) and chemotherapy].
    Kan N; Okino T; Satoh K; Mise K; Teramura Y; Yamasaki S; Harada T; Ohgaki K; Tobe T
    Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1421-7. PubMed ID: 2389941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
    Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
    Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphokines and cancer.
    Cavallo G
    G Batteriol Virol Immunol; 1990; 83(1-12):156-63. PubMed ID: 2133324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxic T lymphocyte therapy of cancer and tumor escape mechanisms.
    Melief CJ; Kast WM
    Semin Cancer Biol; 1991 Oct; 2(5):347-54. PubMed ID: 1773050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-alpha and interleukin-2 in the treatment of renal cell cancer.
    Holdener EE; Emmons RP; Brunda M; Evans L; Levitt D
    Prog Clin Biol Res; 1990; 348():61-9. PubMed ID: 2201034
    [No Abstract]   [Full Text] [Related]  

  • 11. Prospects for tumour therapy using gene transfer.
    Collins MK; Patel P; Flemming CL; Eccles SA
    Bone Marrow Transplant; 1992; 9 Suppl 1():171-3. PubMed ID: 1504662
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhibitory effects of alloimmune T cells on the generation of cytolytic responses of lymphokine-activated killer cells.
    Sugarbaker PH; Matthews W; Steller EP; Eggermont AM
    J Biol Response Mod; 1987 Aug; 6(4):430-45. PubMed ID: 3498012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concepts in immunotherapy of cancer: introduction.
    Ioannides CG; Den Otter W
    In Vivo; 1991; 5(6):551-2. PubMed ID: 1810436
    [No Abstract]   [Full Text] [Related]  

  • 14. Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma.
    Nakano H; Kishida T; Asada H; Shin-Ya M; Shinomiya T; Imanishi J; Shimada T; Nakai S; Takeuchi M; Hisa Y; Mazda O
    J Gene Med; 2006 Jan; 8(1):90-9. PubMed ID: 16097036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic efficacy of tumor-derived heat shock protein 70 immunotherapy combining interleukin-2 on tumor-bearing mice.
    Fu Q; Meng F; Shen X; Guo R
    Chin Med J (Engl); 2003 Feb; 116(2):288-91. PubMed ID: 12775249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity.
    Guo J; Wang B; Zhang M; Chen T; Yu Y; Regulier E; Homann HE; Qin Z; Ju DW; Cao X
    Gene Ther; 2002 Jun; 9(12):793-803. PubMed ID: 12040461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current trends in the biological therapy of malignant tumors].
    Khanson KP; Afanas'ev BV; Bershteĭn LM; Blinov NN; Gershanovich ML; Imianitov EN; Moiseenko VM; Okulov VB; Togo AV
    Vopr Onkol; 1996; 42(5):7-12. PubMed ID: 9064908
    [No Abstract]   [Full Text] [Related]  

  • 19. MHC gene control of the natural killer system at the level of the target and the host.
    Kärre K
    Semin Cancer Biol; 1991 Oct; 2(5):295-309. PubMed ID: 1773046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene therapy of cancer.
    Rosenberg SA
    Important Adv Oncol; 1992; ():17-38. PubMed ID: 1582673
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.